Patents Assigned to Biovail Laboratories, Inc.
-
Patent number: 7241805Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 27, 2006Date of Patent: July 10, 2007Assignee: Biovail Laboratories, Inc.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
-
Publication number: 20050277691Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: August 17, 2005Publication date: December 15, 2005Applicant: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Patent number: 6967218Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: GrantFiled: January 10, 2003Date of Patent: November 22, 2005Assignee: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Publication number: 20050244498Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition for oral administration suitable for once daily dosing. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core.Type: ApplicationFiled: December 3, 2004Publication date: November 3, 2005Applicant: Biovail Laboratories, Inc.Inventors: Pawan Seth, Paul Maes
-
Publication number: 20040185099Abstract: A multiparticulate bisoprolol formulation for once-daily oral administration, each particle of which comprises a core of bisoprolol or a pharmaceutically acceptable salt thereof surrounded by a polymeric coating, the polymeric coating being effective to achieve an initial lag of bisoprolol release in vivo of at least 4-6 hours following administration and thereafter maintaining therapeutic concentrations of bisoprolol for the remainder of the twenty-four hour period. The formulation can be used for night-time dosing so as to minimise the likelihood of acute cardiovascular occurrences in the well-documented high risk period in the morning.Type: ApplicationFiled: April 1, 2004Publication date: September 23, 2004Applicant: Biovail Laboratories, Inc.Inventors: Paul Stark, Catherine Mary Kelly, Niall M. Fanning
-
Patent number: 6733789Abstract: A multiparticulate bisoprolol formulation for once-daily oral administration, each particle of which comprises a core of bisoprolol or a pharmaceutically acceptable salt thereof surrounded by a polymeric coating, the polymeric coating being effective to achieve an initial lag of bisoprolol release in vivo of at least 4-6 hours following administration and thereafter maintaining therapeutic concentrations of bisoprolol for the remainder of the twenty-four hour period. The formulation can be used for night-time dosing so as to minimize the likelihood of acute cardiovascular occurrences in the well-documented high risk period in the morning.Type: GrantFiled: January 20, 2000Date of Patent: May 11, 2004Assignee: Biovail Laboratories, Inc.Inventors: Paul Stark, Catherine Mary Kelly, Niall M. Fanning
-
Publication number: 20030170302Abstract: The invention provides an extended release pharmaceutical tablet containing: (i) a core comprising by weight, based on the core weight, about 70% to about 99% metformin and pharmaceutically acceptable excipients; and (ii) a coating permeable to metformin. The extended release tablet of the invention exhibit a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released; after about 4 hours, from about 15% to about 90% of the metformin is released; after about 8 hours, from about 50% to about 100% of the metformin is released; after about 12 hours, more than about 75% of the metformin is released.Type: ApplicationFiled: December 4, 2002Publication date: September 11, 2003Applicant: Biovail Laboratories, Inc.Inventors: Pawan Seth, Benoit Schmidtt